Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

Bristol Myers continues its dividend legacy with a fresh $0.60 payout per share, marking the 95th straight year of investor ...

The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...

A recent study published in JAMA has found that certain blood pressure medications may raise the risk of serious bleeding in ...

Revlimid (lenalidomide) may interact with drugs like estrogens, erythropoietin-stimulating agents, denosumab, digoxin, and warfarin, which might increase the risk of blood clots or side effects ...